Serum Levels of APRIL Increase in Patients with Glioma, Meningioma and Schwannoma

Autor:	Fouladseresht H; Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. Email: mdoroud@sums.ac.ir, Ziaee SM; Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. Email: mdoroud@sums.ac.ir, Erfani N; Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. Email: mdoroud@sums.ac.ir; Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran., Doroudchi M; Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. Email: mdoroud@sums.ac.ir; Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Jazyk:	angličtina
Zdroj:	Asian Pacific journal of cancer prevention : APJCP [Asian Pac J Cancer Prev] 2019 Mar 26; Vol. 20 (3), pp. 751-756. Date of Electronic Publication: 2019 Mar 26.
DOI:	10.31557/APJCP.2019.20.3.751
Abstrakt:	Objective: Brain tumors are of high mortality and morbidity for which there is still no cure. The TNF family cytokine, A Proliferation Inducing Ligand (APRIL), is shown to help proliferation and development of tumor cells. We assessed serum levels of APRIL in patients with glioma, meningioma and schwannoma in comparison to healthy individuals. Methods: Peripheral blood samples of 68 patients with brain tumors, divided into three groups of gliomas (n=25), meningiomas (n=30) and schwannomas (n=13), as well as 45 healthy individuals were obtained. Serum samples were prepared and stored in -40°C until usage. Using a commercial ELISA method, APRIL concentration was measured in each serum sample. The obtained data were then analyzed using SPSS software. Results: APRIL serum levels were higher in all patients compared to the controls (P<0.001). Moreover, APRIL serum levels were higher in each of the tumor bearing groups (gliomas, meningiomas and schwannomas) in comparison to the controls (P<0.001, <0.001 and =0.001, respectively). Comparing APRIL between the patients groups showed no significant difference. Age and gender showed no significant correlation with serum APRIL levels, although the age of patients in glioma group was significantly lower than controls (P=0.017). The serum APRIL levels in gliomas with histological grade showed no difference, but in meningiomas, it was lower in tumors with higher grades (P= 0.011). Conclusion: Increased serum levels of APRIL in patients with meningioma and schwannoma as well as glioma may indicate a common role of this cytokine in brain tumors. (Creative Commons Attribution License)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu